Marti-Aguado David, Gougol Amir, Gomez-Medina Concepcion, Jamali Arsia, Abo-Zed Abdelrhman, Morales-Arraez Dalia, Jimenez-Sosa Alejandro, Burns Keith, Bawa Aditi, Hernández Anjara, Pujol Claudia, Alvarado-Tapias Edilmar, Szafranska Justyna, Chiu Wai Kan, Villagrasa Ares, Ventura-Cots Meritxell, Gandicheruvu Haritha, Lluch Paloma, Chen Hui-Wei, Rachakonda Vikrant, Duarte-Rojo Andres, Bataller Ramon
Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Digestive Disease Department, Clinic University Hospital, Biomedical Research Institute (INCLIVA), Valencia, Spain.
EClinicalMedicine. 2023 Jun 22;61:102046. doi: 10.1016/j.eclinm.2023.102046. eCollection 2023 Jul.
The prevalence and impact of alcohol withdrawal syndrome (AWS) in patients with alcohol-associated hepatitis (AH) are unknown. In this study, we aimed to investigate the prevalence, predictors, management, and clinical impact of AWS in patients hospitalized with AH.
A multinational, retrospective cohort study enrolling patients hospitalized with AH at 5 medical centres in Spain and in the USA was performed between January 1st, 2016 to January 31st, 2021. Data were retrospectively retrieved from electronic health records. Diagnosis of AWS was based on clinical criteria and use of sedatives to control AWS symptoms. The primary outcome was mortality. Multivariable models controlling for demographic variables and disease severity were performed to determine predictors of AWS (adjusted odds ratio [OR]) and the impact of AWS condition and management on clinical outcomes (adjusted hazard ratio [HR]).
In total, 432 patients were included. The median MELD score at admission was 21.9 (18.3-27.3). The overall prevalence of AWS was 32%. Lower platelet levels (OR = 1.61, 95% CI 1.05-2.48) and previous history of AWS (OR = 2.09, 95% CI 1.31-3.33) were associated with a higher rate of incident AWS, whereas the use of prophylaxis decreased the risk (OR = 0.58, 95% CI 0.36-0.93). The use of intravenous benzodiazepines (HR = 2.18, 95% CI 1.02-4.64) and phenobarbital (HR = 2.99, 95% CI 1.07-8.37) for AWS treatment were independently associated with a higher mortality. The development of AWS increased the rate of infections (OR = 2.24, 95% CI 1.44-3.49), the need for mechanical ventilation (OR = 2.49, 95% CI 1.38-4.49), and ICU admission (OR = 1.96, 95% CI 1.19-3.23). Finally, AWS was associated with higher 28-day (HR = 2.31, 95% CI 1.40-3.82), 90-day (HR = 1.78, 95% CI 1.18-2.69), and 180-day mortality (HR = 1.54, 95% CI 1.06-2.24).
AWS commonly occurs in patients hospitalized with AH and complicates the hospitalization course. Routine prophylaxis is associated with a lower prevalence of AWS. Prospective studies should determine diagnostic criteria and prophylaxis regimens for AWS management in patients with AH.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
酒精性肝炎(AH)患者中酒精戒断综合征(AWS)的患病率及影响尚不清楚。在本研究中,我们旨在调查AH住院患者中AWS的患病率、预测因素、管理情况及临床影响。
在2016年1月1日至2021年1月31日期间,开展了一项多国回顾性队列研究,纳入了在西班牙和美国5个医疗中心住院的AH患者。数据从电子健康记录中回顾性获取。AWS的诊断基于临床标准及使用镇静剂控制AWS症状。主要结局为死亡率。进行多变量模型分析,控制人口统计学变量和疾病严重程度,以确定AWS的预测因素(调整优势比[OR])以及AWS状况和管理对临床结局的影响(调整风险比[HR])。
共纳入432例患者。入院时中位终末期肝病模型(MELD)评分是21.9(18.3 - 27.3)。AWS的总体患病率为32%。较低的血小板水平(OR = 1.61,95%置信区间1.05 - 2.48)和既往AWS病史(OR = 2.09,95%置信区间1.31 - 3.33)与AWS的更高发生率相关,而预防性用药可降低风险(OR = 0.58,95%置信区间0.36 - 0.93)。使用静脉注射苯二氮䓬类药物(HR = 2.18,95%置信区间1.02 - 4.64)和苯巴比妥(HR = 2.99,95%置信区间1.07 - 8.37)治疗AWS与更高的死亡率独立相关。AWS的发生增加了感染率(OR = 2.24,95%置信区间1.44 - 3.49)、机械通气需求(OR = 2.49,95%置信区间1.38 - 4.49)以及入住重症监护病房(ICU)的几率(OR = 1.96,95%置信区间1.19 - 3.23)。最后,AWS与28天(HR = 2.31,95%置信区间1.40 - 3.82)、90天(HR = 1.78,95%置信区间1.18 - 2.69)和180天死亡率(HR = 1.54,95%置信区间1.06 - 2.24)升高相关。
AWS常见于AH住院患者,使住院病程复杂化。常规预防与较低AWS患病率相关。前瞻性研究应确定AH患者AWS管理的诊断标准和预防方案。
本研究未获得公共、商业或非营利部门任何资助机构的特定资助。